253 related articles for article (PubMed ID: 15100273)
1. In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.
Mihalyo MA; Doody AD; McAleer JP; Nowak EC; Long M; Yang Y; Adler AJ
J Immunol; 2004 May; 172(9):5338-45. PubMed ID: 15100273
[TBL] [Abstract][Full Text] [Related]
2. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
Antony PA; Piccirillo CA; Akpinarli A; Finkelstein SE; Speiss PJ; Surman DR; Palmer DC; Chan CC; Klebanoff CA; Overwijk WW; Rosenberg SA; Restifo NP
J Immunol; 2005 Mar; 174(5):2591-601. PubMed ID: 15728465
[TBL] [Abstract][Full Text] [Related]
3. Steady state dendritic cells present parenchymal self-antigen and contribute to, but are not essential for, tolerization of naive and Th1 effector CD4 cells.
Hagymasi AT; Slaiby AM; Mihalyo MA; Qui HZ; Zammit DJ; Lefrancois L; Adler AJ
J Immunol; 2007 Aug; 179(3):1524-31. PubMed ID: 17641018
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
[TBL] [Abstract][Full Text] [Related]
5. CD4+CD25+ regulatory T cells inhibit the antigen-dependent expansion of self-reactive T cells in vivo.
Zwar TD; Read S; van Driel IR; Gleeson PA
J Immunol; 2006 Feb; 176(3):1609-17. PubMed ID: 16424190
[TBL] [Abstract][Full Text] [Related]
6. CD4+ T cells pass through an effector phase during the process of in vivo tolerance induction.
Huang CT; Huso DL; Lu Z; Wang T; Zhou G; Kennedy EP; Drake CG; Morgan DJ; Sherman LA; Higgins AD; Pardoll DM; Adler AJ
J Immunol; 2003 Apr; 170(8):3945-53. PubMed ID: 12682221
[TBL] [Abstract][Full Text] [Related]
7. Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen.
Higgins AD; Mihalyo MA; Adler AJ
J Immunol; 2002 Oct; 169(7):3622-9. PubMed ID: 12244153
[TBL] [Abstract][Full Text] [Related]
8. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.
Sakaguchi S; Sakaguchi N; Asano M; Itoh M; Toda M
J Immunol; 1995 Aug; 155(3):1151-64. PubMed ID: 7636184
[TBL] [Abstract][Full Text] [Related]
9. Impact of effector cell differentiation on CD4+ T cells that evade negative selection by a self-peptide.
Boesteanu A; Rankin AL; Caton AJ
Int Immunol; 2006 Jul; 18(7):1017-27. PubMed ID: 16702167
[TBL] [Abstract][Full Text] [Related]
10. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
11. CD4 cell priming and tolerization are differentially programmed by APCs upon initial engagement.
Higgins AD; Mihalyo MA; McGary PW; Adler AJ
J Immunol; 2002 Jun; 168(11):5573-81. PubMed ID: 12023353
[TBL] [Abstract][Full Text] [Related]
12. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Bristol JA; Schlom J; Abrams SI
Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells.
Brode S; Raine T; Zaccone P; Cooke A
J Immunol; 2006 Nov; 177(10):6603-12. PubMed ID: 17082572
[TBL] [Abstract][Full Text] [Related]
14. Self-thyroid epithelial cell (TEC)-reactive CD8+ T cell lines/clones derived from autoimmune thyroiditis lesions. They recognize self-thyroid antigens directly on TEC to exhibit T helper cell 1-type lymphokine production and cytotoxicity against TEC.
Sugihara S; Fujiwara H; Niimi H; Shearer GM
J Immunol; 1995 Aug; 155(3):1619-28. PubMed ID: 7543527
[TBL] [Abstract][Full Text] [Related]
15. Treatment with cyclophosphamide supported by various dendritic cell-based vaccines induces diversification in CD4⁺ T cell response against MC38 colon carcinoma.
Wojas-Turek J; Szczygieł A; Kicielińska J; Rossowska J; Piasecki E; Pajtasz-Piasecka E
Int J Oncol; 2016 Feb; 48(2):493-505. PubMed ID: 26648160
[TBL] [Abstract][Full Text] [Related]
16. T-bet down-modulation in tolerized Th1 effector CD4 cells confers a TCR-distal signaling defect that selectively impairs IFN-gamma expression.
Long M; Slaiby AM; Hagymasi AT; Mihalyo MA; Lichtler AC; Reiner SL; Adler AJ
J Immunol; 2006 Jan; 176(2):1036-45. PubMed ID: 16393991
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit.
Costa GL; Sandora MR; Nakajima A; Nguyen EV; Taylor-Edwards C; Slavin AJ; Contag CH; Fathman CG; Benson JM
J Immunol; 2001 Aug; 167(4):2379-87. PubMed ID: 11490028
[TBL] [Abstract][Full Text] [Related]
18. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes.
Evans R; Kamdar SJ; Duffy T; Edison L
J Immunol; 1993 Jan; 150(1):177-84. PubMed ID: 8417123
[TBL] [Abstract][Full Text] [Related]
19. Analysis of effector cells in tumor-bearing mice pre-treated with active specific immunization followed by cyclophosphamide.
Li L; Okino T; Kan N; Yamasaki S; Ichinose Y; Sugie T; Kanaoka S; Imamura M
Biotherapy; 1998; 11(4):223-8. PubMed ID: 9950097
[TBL] [Abstract][Full Text] [Related]
20. Histone acetylation at the Ifng promoter in tolerized CD4 cells is associated with increased IFN-gamma expression during subsequent immunization to the same antigen.
Long M; Slaiby AM; Wu S; Hagymasi AT; Mihalyo MA; Bandyopadhyay S; Vella AT; Adler AJ
J Immunol; 2007 Nov; 179(9):5669-77. PubMed ID: 17947638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
